Development of antibody–oligonucleotide complexes for targeting exosomal microrna

23Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

MicroRNAs in exosomes (exosomal miRNAs) are considered as significant targets for cancer therapy. Anti-miR oligonucleotides are often used for the functional inhibition of miRNAs; however, there are no studies regarding the regulation of exosomal miRNA functions. In this study, we attempted to develop a novel drug delivery system using anti-exosome antibody–anti-miR oligonucleotide complexes (ExomiR-Tracker) to hijack exosomes to carry anti-miR oligonucleotides inside exosome-recipient cells. We found that ExomiR-Tracker bound to the exosomes, and then the complexes were introduced into the recipient cells. We also found that anti-miR oligonucleotides introduced into the recipient cells can exhibit inhibitory effects on exosomal miRNA functions in vitro and in vivo. We believe that our strategy would be a promising one for targeting exosomal miRNAs.

Cite

CITATION STYLE

APA

Yamayoshi, A., Oyama, S., Kishimoto, Y., Konishi, R., Yamamoto, T., Kobori, A., … Murakami, A. (2020). Development of antibody–oligonucleotide complexes for targeting exosomal microrna. Pharmaceutics, 12(6), 1–12. https://doi.org/10.3390/pharmaceutics12060545

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free